{"NCTID":"NCT05918640","clinicalTrial":{"derivedSection":{"conditionBrowseModule":{"ancestors":[{"id":"D012516","term":"Osteosarcoma"},{"id":"D018213","term":"Neoplasms, Bone Tissue"},{"id":"D009372","term":"Neoplasms, Connective Tissue"},{"id":"D018204","term":"Neoplasms, Connective and Soft Tissue"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D012509","term":"Sarcoma"}],"meshes":[{"id":"D012512","term":"Sarcoma, Ewing"},{"id":"D058405","term":"Desmoplastic Small Round Cell Tumor"},{"id":"D009369","term":"Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"C568606","term":"PM 01183"}]},"miscInfoModule":{"versionHolder":"2026-01-07"}},"hasResults":false,"protocolSection":{"armsInterventionsModule":{"armGroups":[{"description":"The first part of this study is a standard 3+3 design to test the safety, tolerability and pharmacokinetic profile of lurbinectedin administered on a day 1, 4 schedule in patients with FET-fusion tumors.","interventionNames":["Drug: Lurbinectedin"],"label":"Ewing Sarcoma","type":"EXPERIMENTAL"}],"interventions":[{"armGroupLabels":["Ewing Sarcoma"],"description":"Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days.\nDoses will be determined in the phase 1 portion of the trial.","name":"Lurbinectedin","type":"DRUG"}]},"conditionsModule":{"conditions":["Ewing Sarcoma","Desmoplastic Small Round Cell Tumor","Pediatric Cancer","Undifferentiated Sarcoma"],"keywords":["Ewing Sarcoma-Friend Leukemia Integration 1 Transcription factor (ESW-FLI1)","Ewing Sarcoma Breakpoint Region 1-Friend Leukemia Integration 1 Transcription factor (EWSR1-FLI1)","Ewing Sarcoma Erythroblast Transformation Specific Related Gene (EWS-ERG)","Ewing Sarcoma Breakpoint Region 1 (EWRS1)","TATA-Box-Binding Protein Associated Factor 15 (TAF15)","Fused Tumors (FET)","Ewing Sarcoma-Wilms' Tumor Gene 1 (EWS-WT1)"]},"contactsLocationsModule":{"centralContacts":[{"email":"LAETSCHT@chop.edu","name":"Theodore Laetsch, MD","phone":"267-425-5544","role":"CONTACT"},{"email":"22DT011@CHOP.EDU","name":"Meghan Donnelly","phone":"267-426-9343","role":"CONTACT"}],"locations":[{"city":"Los Angeles","contacts":[{"email":"leo.mascarenhas@cshs.org","name":"Leo Mascarenhas, MD","phone":"310-423-4423","role":"CONTACT"},{"email":"emilie.douine-barthelemy@cshs.org","name":"Emilie Douine-Barthelemy","phone":"310-967-0692","role":"CONTACT"}],"country":"United States","facility":"Cedars-Sinai Medical Center","geoPoint":{"lat":34.05223,"lon":-118.24368},"state":"California","status":"RECRUITING","zip":"90048"},{"city":"Iowa City","contacts":[{"email":"jenna-gedminas@uiowa.edu","name":"Jenna Gedminas, MD","phone":"319-353-6393","role":"CONTACT"},{"email":"Chris-Stamy@uiowa.edu","name":"Chris Stamy","phone":"319-356-7875","role":"CONTACT"},{"name":"Jenna Gedminas, MD","role":"PRINCIPAL_INVESTIGATOR"}],"country":"United States","facility":"University of Iowa Hospitals and Clinics","geoPoint":{"lat":41.66113,"lon":-91.53017},"state":"Iowa","status":"RECRUITING","zip":"52242"},{"city":"Boston","contacts":[{"email":"steven.dubois@dfci.harvard.edu","name":"Steven Dubois, MD","phone":"617-632-5460","role":"CONTACT"},{"email":"alexandra_sala@dfci.harvard.edu","name":"Alexandra Sala","phone":"857-215-2410","role":"CONTACT"},{"name":"Steven Dubois, MD","role":"PRINCIPAL_INVESTIGATOR"}],"country":"United States","facility":"Dana-Farber Cancer Institute","geoPoint":{"lat":42.35843,"lon":-71.05977},"state":"Massachusetts","status":"RECRUITING","zip":"02215"},{"city":"Ann Arbor","contacts":[{"email":"rashmim@med.umich.edu","name":"Rashmi Chugh, MD","phone":"800-865-1125","role":"CONTACT"},{"email":"CancerAnswerLine@med.umich.edu","name":"Cancer AnswerLine","phone":"1-800-865-1125","role":"CONTACT"},{"name":"Rashmi Chugh, MD","role":"PRINCIPAL_INVESTIGATOR"}],"country":"United States","facility":"University of Michigan","geoPoint":{"lat":42.27756,"lon":-83.74088},"state":"Michigan","status":"RECRUITING","zip":"48109"},{"city":"New York","contacts":[{"email":"gladebej@mskcc.org","name":"Julia Glade Bender, MD","phone":"212-639-6729","role":"CONTACT"},{"email":"makir@mskcc.org","name":"Robert Maki, MD","phone":"646-888-5059","role":"CONTACT"},{"name":"Julia Glade Bender, MD","role":"PRINCIPAL_INVESTIGATOR"}],"country":"United States","facility":"Memorial Sloan Kettering Cancer Center","geoPoint":{"lat":40.71427,"lon":-74.00597},"state":"New York","status":"RECRUITING","zip":"10065"},{"city":"Philadelphia","contacts":[{"email":"CancerTrials@CHOP.EDU","name":"Theodore Laetsch, MD","phone":"267-425-5544","role":"CONTACT"},{"email":"22DT011@CHOP.EDU","name":"Meghan Donnelly","phone":"267-426-9343","role":"CONTACT"}],"country":"United States","facility":"Children's Hospital of Philadelphia","geoPoint":{"lat":39.95238,"lon":-75.16362},"state":"Pennsylvania","status":"RECRUITING","zip":"19104"}],"overallOfficials":[{"affiliation":"Children's Hospital of Philadelphia","name":"Theodore Laetsch, MD","role":"PRINCIPAL_INVESTIGATOR"}]},"descriptionModule":{"briefSummary":"The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.","detailedDescription":"In this study, the investigators will test the activity of lurbinectedin as a targeted therapy for FET (FUS, Ewing Sarcoma Breakpoint Region 1 (EWRS1), TATA-Box-Binding Protein Associated Factor 15 (TAF15)).\nEwing sarcoma is driven by the Ewing Sarcoma-Friend Leukemia Integration 1 Transcription Factor (EWS-FLI1).\nLurbinectedin has been shown to inhibit EWS-FLI1 and Ewing Sarcoma-Wilms' Tumor Gene 1 (EWS-WT1) in preclinical models.\nTherefore, the goal of this study is to see if Lurbinectedin can be used to inhibit EWS-FLI1, EWS-WT1, or other FET fusion proteins to drive tumor responses in patients."},"designModule":{"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","interventionModelDescription":"The first part of this study is a standard 3+3 design to test the safety, tolerability and pharmacokinetic profile of lurbinectedin administered on a day 1, 4 schedule in patients with FET-fusion tumors.\nThe second part of this study is a single-stage phase 2 design and will accrue 17 patients in parallel to the exploratory cohort after the Recommended Phase 2 Dose (RP2D) is determined.","maskingInfo":{"masking":"NONE"},"primaryPurpose":"TREATMENT"},"enrollmentInfo":{"count":63,"type":"ESTIMATED"},"phases":["PHASE1","PHASE2"],"studyType":"INTERVENTIONAL"},"eligibilityModule":{"eligibilityCriteria":"

Inclusion Criteria:

Age ≥ 10 years.
Phase 1: Histological confirmed diagnosis of recurrent or relapsed solid tumor failing primary therapy.\nPatients must have a known FET fusion (fusion that contains EWSR1, FUS, or TAF15) as documented by next generation sequencing, polymerase chain reaction (PCR) or Fluorescence in situ hybridization (FISH).\nPatients with a histological diagnosis of Ewing sarcoma with EWS-FLI1 are eligible for dose escalation but not for the exploratory cohort.\nPlease note patients with Ewing sarcoma and alternative FET-ETS fusions (including but not limited to EWS-ERG, EWS-ETV1, EWS-ETV4, EWS-FEV, FUS-ERG, FUS-FEV) are eligible for the exploratory cohort.
Phase 2: Histologically confirmed diagnosis of recurrent or relapsed Ewing sarcoma failing primary therapy with confirmation of EWS-FLI1 fusion and breakpoint by Next generation sequencing or PCR or EWSR1 rearrangement confirmed by FISH and available tissue for central confirmation of EWS-FLI1 fusion and breakpoint.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 (age ≥16 years) or Lansky of at least 60 (age <16 years).
Disease status (baseline imaging must be performed within 28 days of Day 1 of study treatment):
1. Phase 1: At least one site of measurable disease on CT or MRI as defined by RECIST 1.1 OR evaluable disease with at least one site of disease that has not been previously radiated
2. Phase 2: At least one site of measurable disease on CT or MRI as defined by RECIST 1.1
Meets organ function requirements as outlined below:
1. Liver:
  Alanine aminotransferase (ALT) ≤ 2.5X upper limit of normal.\nFor the purposes of this study the upper limit of normal for ALT is 45 U/L.\nAspartate aminotransferase (AST) ≤ 2.5X upper limit of normal.\nFor the purposes of this study the upper limit of normal for AST is 50 U/L.\nTotal bilirubin ≤ 1.5X institutional upper limit of normal with the exception of patients with Gilbert's syndrome who must have bilirubin <3X institutional upper limit of normal.
2. Renal:
  Creatinine Calculated creatinine clearance (by the Schwartz equation for patients <18 years of age and Cockroft-Gault formula (Appendix B) for patients ≥18 years of age) or radionuclide glomerular filtration rate (GFR) ≥ 50 mL/min /m2 or a serum creatinine less than or equal to the age/gender valued below:
  Age Maximum Serum Creatinine (mg/dL) Male Female 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4
  ≥ 16 years 1.7 1.4
3. Bone marrow:
  Absolute Neutrophil Count (ANC) ≥ 1,000/µL (>one week since last dose of short acting medications (e.g.\nfilgrastim) and > two weeks since last dose of long acting medications (e.g.\npeg-filgrastim)) Platelet Count (PLTs) ≥ 100,000/ µL (>two weeks since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days of screening laboratories) Patients with a history of bone marrow involvement are required to have bilateral bone marrow aspirates and biopsies at baseline.\nSubjects with bone marrow disease are eligible as long as they meet the hematologic requirements above and are not known to be refractory to red cell or platelet transfusions.
4. Cardiac:
Creatine phosphokinase ≤ 2.5 x institutional upper limit of normal, Left ventricular ejection fraction (LVEF) or shortening fraction (SF) per institutional norm LVEF > 50% OR SF >28%.
Written, voluntary informed consent
Fertile males and females of childbearing potential must agree to use an effective method of birth control from screening, through 6 months after last study drug administration for females and 4 months for males.\nWomen of childbearing potential must have a negative pregnancy test during screening procedures.\nEffective methods of birth control include: double barrier method (condom, diaphragm), abstinence, an intrauterine device (IUD), levonorgestrol implants, medroxyprogesterone acetate injections, or oral contraception.\nFor those subjects whose preferred and usual lifestyle employs abstinence, refraining from heterosexual intercourse must be practiced during the entire active phase of the trial.
Patients ≥18 years must be willing to undergo tumor biopsy at study entry.\nPatients with Ewing sarcoma or DSRCT must be willing to undergo biopsy post-treatment.\nIf biopsy is contraindicated, enrollment must be approved by study PI and archival tissue must be available.
Time elapsed from previous therapy:
1. Must be ≥ 3 weeks for systemic myelosuppressive therapy
2. ≥ 2 weeks for local radiation therapy (small field), ≥ 150 days after thyrotropin binding inhibition (TBI), craniospinal external beam radiotherapy (XRT) or radiation to ≥50% of the pelvis
3. ≥ 2 weeks for major surgery
4. ≥ 2 weeks for monoclonal antibodies and oral kinase inhibitors.
5. ≥ 6 weeks for autologous stem cell transplant.\n6 months for allogeneic stem cell transplant.
6. ≥ 6 weeks for any type of cellular therapy
Patients must be recovered to baseline or Grade ≤1from the acute adverse effects of prior treatments, with the exception of alopecia and decreased deep tendon reflexes.

Exclusion Criteria:

Prior therapy with trabectedin or lurbinectedin.
Subjects with known brain metastases.
Subjects with a known bleeding diathesis.
Subjects who are pregnant or breastfeeding.
Concurrent therapy:
1. Patients who are currently receiving an investigational drug or another anticancer agent
2. Patients receiving over the counter or herbal supplement with significant potential hepatotoxicity in the opinion of the investigator.
3. Patients receiving a medically necessary strong or moderate CYP3A4 inhibitor or inducer within 14 days prior to the first dose of study drug.
Clinically significant, unrelated illness or uncontrolled infection which would, in the opinion of the treating physician, compromise the patient's ability to tolerate the investigational agents or be likely to interfere with the study procedures or results.
Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.
Patients with known active viral hepatitis (i.e.\nHepatitis A, B, or C)

","healthyVolunteers":false,"minimumAge":"10 Years","sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"identificationModule":{"acronym":"LiFFT","briefTitle":"Lurbinectedin in FET-Fused Tumors","nctId":"NCT05918640","officialTitle":"Lurbinectedin in FET-Fusion Tumors (LIFFT)","orgStudyIdInfo":{"id":"23-020814"},"organization":{"class":"OTHER","fullName":"Children's Hospital of Philadelphia"}},"ipdSharingStatementModule":{"ipdSharing":"NO"},"outcomesModule":{"primaryOutcomes":[{"description":"First cycle (approximately 21 days) Dose Limiting Toxicities (DLTs) will be evaluated.","measure":"Phase 1: Dose Limiting Toxicities (DLTs)","timeFrame":"within 28 days of the first dose"},{"description":"Adverse events to be reported during treatment and for at least 28 days after last dose.","measure":"Phase 1: Frequency of adverse events","timeFrame":"28 days after last dose"},{"description":"Percentage of participants with complete response or partial response will be assessed approximately every 2 to 4 cycles through the end of treatment and up to at least 28 days after the last dose.","measure":"Phase 1: Complete Response or Partial Response","timeFrame":"through the end of treatment, an average of 1 year"},{"description":"Event-free survival (EFS) is based on investigator assessment from baseline until Month 24.","measure":"Phase 2: Event-Free Survival (EFS)","timeFrame":"2 years"}],"secondaryOutcomes":[{"description":"Maximum observed plasma concentration (Cmax) will be used to assess Lurbinectedin Pharmacokinetics","measure":"Phase 1: Maximum observed Plasma Concentration (Cmax)","timeFrame":"at the end of cycle 1 (each cycle is 28 days)"},{"description":"Area under the concentration-time curve (AUC) will be used to assess Lurbinectedin Pharmacokinetics","measure":"Phase 1: Area under the concentration-time curve (AUC)","timeFrame":"at the end of cycle 1 (each cycle is 28 days)"},{"description":"Progression Free Survival (PFS) assessed from the first dose of study drug to earliest date of death or progressive disease.","measure":"Phase 2: 6-month Progression Free Survival (PFS)","timeFrame":"6 months"},{"description":"Duration of Response (DoR) defined as time from date of first response (Complete Response or Partial Response) in responders to date of progression or death","measure":"Phase 1: Duration of Response (DoR)","timeFrame":"Up to 5 years"},{"description":"Overall survival (OS) defined as the time from enrollment to date of death due to any cause.","measure":"Phase 2: Overall Survival","timeFrame":"Up to 5 years"},{"description":"Disease Control ate is defined as the percentage of patients who sustain a complete response, partial response, or stable disease over 5 years.","measure":"Phase 2: Disease Control Rate","timeFrame":"Up to 5 Years"}]},"oversightModule":{"isFdaRegulatedDevice":false,"isFdaRegulatedDrug":true,"oversightHasDmc":true},"sponsorCollaboratorsModule":{"collaborators":[{"class":"INDUSTRY","name":"Jazz Pharmaceuticals"},{"class":"OTHER","name":"Stand Up To Cancer"}],"leadSponsor":{"class":"OTHER","name":"Children's Hospital of Philadelphia"},"responsibleParty":{"type":"SPONSOR"}},"statusModule":{"completionDateStruct":{"date":"2028-07-30","type":"ESTIMATED"},"expandedAccessInfo":{"hasExpandedAccess":false},"lastUpdatePostDateStruct":{"date":"2025-11-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2025-11-20","overallStatus":"RECRUITING","primaryCompletionDateStruct":{"date":"2026-07-30","type":"ESTIMATED"},"startDateStruct":{"date":"2023-07-27","type":"ACTUAL"},"statusVerifiedDate":"2025-11","studyFirstPostDateStruct":{"date":"2023-06-26","type":"ACTUAL"},"studyFirstSubmitDate":"2023-06-06","studyFirstSubmitQcDate":"2023-06-15"}}},"labeledClinicalTrialsCriteria":{"included":{},"ref":{"_type":"DocumentReference","path":"apps/clinicalTrials/clinicalTrialsTrees/NCT05918640-GMiulNhUPGrzlsCN3Fmv"},"snapshot":{"exists":false,"id":"NCT05918640-GMiulNhUPGrzlsCN3Fmv","ref":{"_type":"DocumentReference","path":"apps/clinicalTrials/clinicalTrialsTrees/NCT05918640-GMiulNhUPGrzlsCN3Fmv"}}}}

In triage

In Design

Ready to code

Coding

Done

Create new task

Created by me

Assigned to me

Score calculator